Navigation Links
Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline

ABBOTT PARK, Ill., April 25 /PRNewswire-FirstCall/ -- Abbott's broad portfolio of businesses and expanding global operations generated outstanding 2007 results, and its new product pipeline provides a foundation for continued growth as demonstrated by the company's strong first-quarter performance, Chairman and Chief Executive Officer Miles D. White told shareholders today at the company's annual meeting.

"2007 was an outstanding year for Abbott across all of our major businesses and our strong momentum has carried into 2008," said Mr. White. "We delivered another year of strong sales and profitability. We expanded our business in important emerging economies such as China, India, Russia and Latin America. And we were highly productive in building our pipeline, providing the basis for a steady new product stream and continued future success."

Business Mix Drives Results

Significant contributions from each of the company's major businesses -- diabetes care, diagnostics, nutritionals, pharmaceuticals and vascular -- drove a 15 percent increase in 2007 sales. Abbott's stock also outperformed the S&P 500 Index and the majority of its peers, delivering a total return to shareholders of 18 percent in 2007 (stock price growth plus dividends). This marked the second straight year Abbott outpaced the S&P 500 and most of its peers; in 2006, its stock had a total return of 27 percent.

"The diversity and balance of our business base is our core strength and Abbott's greatest differentiator," said Mr. White. "Our continued strong growth through the challenges that face medical technology innovators speaks to our ability to adapt, execute and optimize the many prospects that our mix of businesses provides."

International Growth

While the United States remains Abbott's single largest market, the company's growing international business has been central to its performance. For the first time in Abbott's 120-year history, the company's mix of total revenues in 2007 favored its international business.

In 2007, Abbott's diabetes care sales increased 18 percent internationally; international nutritionals grew 18 percent; the international pharmaceutical business delivered sales growth of nearly 17 percent; and diagnostics enjoyed strong growth in Europe, Latin America and Japan.

New Products

A major component of Abbott's success is the innovation of new products to serve patients. Abbott plans a record number of new product introductions in 2008:
-- Already in 2008, the company has introduced two new indications for

HUMIRA(R) (adalimumab) -- moderate to severe plaque psoriasis and

moderate to severely active polyarticular juvenile idiopathic

arthritis, both of which received U.S. Food and Drug Administration

(FDA) approval in the first quarter. Abbott also received approval

from the Japanese Ministry of Health, Labour and Welfare for HUMIRA for

the treatment of rheumatoid arthritis in patients with inadequate

response to conventional therapy.

-- SIMCOR(R), a fixed-dose combination of Niaspan(R) (Abbott's proprietary

niacin extended-release) and simvastatin that targets both "good" and

"bad" cholesterol in a single pill, was also approved by the FDA in the

first quarter.

-- Abbott broadened its line of glucose meters with the launch of the

FreeStyle Freedom(R) Lite and received U.S. approval for its FreeStyle

Navigator(R) Continuous Glucose Monitoring System.

-- Abbott introduced the ARCHITECT i1000SR immunochemistry analyzer in the

United States. Designed to help improve productivity in small-volume

labs, the instrument addresses common laboratory workflow challenges

through innovative sample processing and reagent management.

-- Abbott expects to launch its XIENCE(TM) V drug-eluting stent in the

United States in the second quarter. XIENCE V was launched in Europe

and other international markets beginning in late 2006.

-- A controlled-release form of Abbott's pain reliever Vicodin was

submitted for U.S. regulatory approval in the fourth quarter of 2007.

-- TriLipix(TM), a next-generation fenofibrate for lipid management, was

submitted for U.S. regulatory approval in the fourth quarter of 2007.

Mr. White said the company is also conducting highly innovative research and development work across its range of medical products, nutritional and pharmaceutical businesses.

Shareholder Proposals

During the meeting, shareholders rejected proposals calling for a non-binding vote on executive compensation and access to medicines. In addition, the shareholders ratified the selection of Deloitte & Touche LLP as auditors of the corporation for 2008.

Abbott's 13 incumbent directors were elected to the board of directors during the annual meeting. They are listed below:

-- Roxanne S. Austin, president, Austin Investment Advisors.

-- William M. Daley, head of the office of corporate social responsibility

and chairman of the midwest, JPMorgan Chase & Co.

-- W. James Farrell, retired chairman and chief executive officer,

Illinois Tool Works Inc.

-- H. Laurance Fuller, retired co-chairman of the board, BP Amoco, p.l.c.

-- William A. Osborn, chairman and former chief executive officer,

Northern Trust Corporation and The Northern Trust Company.

-- The Rt. Hon. Lord Owen CH, chairman of Europe Steel, p.l.c.

-- Boone Powell Jr., retired chairman, Baylor Health Care System.

-- W. Ann Reynolds, Ph.D., former president, The University of Alabama at


-- Roy S. Roberts, managing director, Reliant Equity Investors.

-- Samuel C. Scott III, chairman, president and chief executive officer,

Corn Products International, Inc.

-- William D. Smithburg, retired chairman, president and chief executive

officer, The Quaker Oats Company.

-- Glenn F. Tilton, chairman, president and chief executive officer, UAL

Corporation and United Air Lines, Inc., a wholly owned subsidiary of

UAL Corporation.

-- Miles D. White, chairman of the board and chief executive officer,


About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
2. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
3. Abbott Scientists Create One Molecule With Two Antibody Functions
4. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
5. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
6. Abbott Declares 336th Consecutive Quarterly Dividend
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Abbott to Present at JP Morgan Healthcare Conference
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Post Your Comments:
(Date:10/9/2017)... ... 09, 2017 , ... At its national board meeting in North Carolina, ... University’s Departments of Physics and Astronomy, has been selected for membership in ARCS ... for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... providing advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience ... application consulting, Nanoscience Analytical offers a broad range of contract analysis services ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... healthcare and technology sector at their fourth annual Conference where founders, investors, innovative ... speakers and the ELEVATE pitch competition showcasing early stage digital health and med ...
(Date:10/5/2017)... ... October 05, 2017 , ... Understanding the microbiome, the millions ... human health. Gut Love: You Are My Future, the newest exhibit on display at ... it explores the human condition through the lens of the gut microbiome. , ...
Breaking Biology Technology:
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at . 2016 Year ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):